Immunogenic Chemotherapy: Discovery of a Critical Protein through Proteomic Analyses of Tumor Cells

Cancer Genomics - Proteomics

FRANÇOIS GHIRINGHELLI²  GIAN MARIA FIMIA¹  LIONEL APETOH²  GUIDO KROEMER³  LAURENCE ZITVOGEL²  MAURO PIACENTINI³  ANTOINE TESNIERE³  MICHEL OBEID³ 

[1] ational Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, I-00149 Rome, Italyational Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, I-00149 Rome, Italyational Institute for Infectious Diseases Lazzaro Spallanzani, Via Portuense 292, I-00149 Rome, Italy;nstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U805, CIC BT507, Villejuifnstitut Gustave Roussy, Villejuifnstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U805, CIC BT507, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U805, CIC BT507, Villejuifnstitut National de la Santé et de la Recherche Médicale, U805, CIC BT507, Villejuifnstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U805, CIC BT507, Villejuif;nstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U848, Villejuif, Francenstitut Gustave Roussy, Villejuifnstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U848, Villejuif, Franceaculté Paris Sud-Université Paris XI, Villejuifnstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U848, Villejuif, Francenstitut National de la Santé et de la Recherche Médicale, U848, Villejuif, Francenstitut Gustave Roussy, Villejuifaculté Paris Sud-Université Paris XI, Villejuifnstitut National de la Santé et de la Recherche Médicale, U848, Villejuif, France

关键词: Calreticulin;    proteomics;    tumor cell;    antitumor vaccination;    chemotherapy;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

The aim of chemotherapy and radiotherapy is to eliminate tumor cells. While the outcomes of these cytotoxic treatments have previously been assigned to their direct effects on tumor cells, recent findings have shown that the host's immune system also contributes to the success of chemotherapeutic and radiotherapeutic regimens. The finding that some cytotoxic antitumor coumpounds such as anthracyclines were capable of triggering a potent T-cell-dependent antitumor response has prompted the search for molecular determinants responsible for the immunogenicity of anthracyclines. Proteomic analyses of anthracycline-treated tumor cells have recently revealed the critical involvement of calreticulin in mediating the immunogenicity of dying tumor cells. Here, we focused on the molecular study of immunogenic chemotherapy which led to the characterization of calreticulin as a critical protein in immunogenic cancer cell death.

【 授权许可】

Unknown